Amanda Moore, the midwife who died at her home in Calgary in May, had never heard of the drug thiopental before it was first approved by Health Canada in 2006.
But she said she was shocked when she read the instructions for the drug, which is prescribed to people who have had surgery for cancer or are at high risk for infection.
“They just don’t mention it in the information about thiopenthals that we were getting,” said Moore, who was an associate professor of midwifery at the University of Alberta.
“And I was like, ‘Oh, my God, that’s not the way that it was meant to be taken.
‘And I’m just like, I don’t know how you’re supposed to know what that means.'”
Midwives can take the drug to treat heartburn, bronchitis and some forms of pneumonia.
The drug is not approved for use in people who already have these conditions, nor for people with diabetes, high blood pressure or heart disease.
Moore, a nurse practitioner, told the CBC that she thought the drug’s instructions about thiosal was “wrong,” especially given the fact that it is not an approved treatment for anyone who has had surgery or is at high-risk for infection, but was still prescribed to other people.
“I’ve never heard anything about thiazoles before, and I was just like: ‘I don’t understand,'” Moore said.
She then emailed the Canadian Pharmacy Association to complain.
“They said, ‘Hey, this drug is prescribed for certain conditions.
We know that there are certain conditions that can cause these side effects.’
And I said, well, that would explain it.”
Moore said she never saw the information on the drug at her doctor’s office, and her questions were not answered.
“But I’m a licensed midwife,” she said.
“So I’m like, if they know that I have a specific condition, why don’t they have the instructions?
But that’s the way they have to be with all these things.””
And so, I said that I don.
But that’s the way they have to be with all these things.”
The drug is also approved for people at high potential for infection with tuberculosis, but the FDA has not approved it for people who are at low-risk.
“In my experience, I’ve never been in a situation where they’ve given me information on what the drug does and said, you know, ‘Well, you need to take it now,'” Moore told the BBC.
“So, they’re saying to me, ‘We’re not really sure what it’s supposed to do, and we’re not sure that we need to do this.'”
Moore said her experience in prescribing the drug was not uncommon.
“There’s a lot of midwives in the community who are very concerned about this drug,” she told the broadcaster.
“And they’re just like saying, ‘Please, you can’t give us a warning, because this is dangerous.'”
Moore was not the only one to be disappointed by the drug instructions.
Midwives in Canada have been trying to understand the drug since the drug came into use.
“It’s not as if there’s not some information on thiazolyl chloride and the risks and benefits, and what it does to the body,” said Laurie Aylward, a clinical professor of clinical psychology at Dalhousie University in Halifax.
“But I would hope that if there was something that would make sense, that they would have given it a better description.”
Midwives who have used thiopethionate for years, but are still trying to figure out its benefits and risks, have told the Canadian Medical Association about concerns about the drug.
The AMA says its position on thiopetheon is that it can cause some side effects, including fever, headache and muscle spasms, but these symptoms are usually mild.
“As a general rule, patients should avoid thiopsychoses, as these drugs have been shown to cause mild or moderate side effects in clinical trials,” the AMA said in a statement.
“These side effects include headache, vomiting, muscle spasm and diarrhea.
Patients should also consider thiopatheon when deciding if they need a repeat thiopectomy.”
The AMA’s position on Thiopethanol has also changed.
Aylwards said she has now started reading a lot more about the side effects of thiophenyl chloride.
“What I’m finding is that they don’t necessarily have the information that I would have had before I took the drug,” Aylsward said.
The AMA has also published a blog post with links to a variety of studies that have found that patients who take thiopothionate have more blood clotting problems than those who do not take the medication.
A study published in the Journal of the American Medical Association in May found that thiophenylt